Trials / Completed
CompletedNCT00413192
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the therapeutic activity and safety of E7389 in patients with advanced/metastatic soft tissue sarcoma who have failed standard chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7389 | 1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days. |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2012-06-01
- Completion
- 2013-02-01
- First posted
- 2006-12-19
- Last updated
- 2017-04-26
- Results posted
- 2017-03-22
Locations
15 sites across 5 countries: Belgium, Denmark, France, Germany, Poland
Source: ClinicalTrials.gov record NCT00413192. Inclusion in this directory is not an endorsement.